Clinical targets in Chronic Kidney Disease – Bone Mineral Disorder (CKD-MBD)

Knowledge Exchange is an online interactive write papers for me conference series that focuses on recent advances in Chronic Kidney Disease management. The content of the expert statements in the videos reflects the personal opinion of the experts and does not necessarily reflect the opinion of Shire. example of descriptive essay All interviews were initiated, organized and funded by Shire. These videos were recorded during Knowledge Exchange webinar.

What are the therapeutic targets in CKD-MBD?

Do you think that the therapeutic targets for Chronic Kidney Disease (CKD) have been clearly defined?

This video highlights how observational outline example for research paper studies such do my homework canada as COSMOS, which investigates the association between CKD-MBD laboratory parameters, are redefining the therapeutic targets for End Stage Renal Disease (ESRD).,1

Please click here to view Professor Cannata-Andia’s presentation.

1. Fernàndez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30(9):1542-1551.

The impact of serum phosphate levels in CKD-MBD disease progression

Why is it important to define optimal serum phosphate levels in CKD patients? Watch Professor Cozzolino in the video below to learn about the effects of hyperphosphatemia and the associated unfavourable outcomes in Chronic Kidney Disease dialysis patients.1  This presentation focuses on why patient adherence to phosphate binders is an important part of CKD patient management.2

Please click here to view Professor Cozzolino’s presentation.

1.Galassi A, Cupisti A, Santoro A, Cozzolino M. Phosphate balance in ESRD: diet, dialysis and binders against low evident masked pool. J Nephrol. 2015;28:415-29.
2.Covic A and Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153.

Applying KDIGO guidelines in clinical practice

Are you up-to-date on the recent changes to the KDIGO guidelines? Follow Professor Ketteler below as he provides the rationale for the 2017 update to the KDIGO guidelines and discusses how these updates may impact the treatment of Chronic Kidney Disease (CKD). This presentation focuses on the updates concerning serum calcium and phosphate levels in CKD patients.1

Please click here to view Professor Ketteler‘s presentation.

1.KDIGO 2017 Clinical Practice Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements. 2017;7;1-59.

DISCLAIMER: USE OF CLINICAL PRACTICE GUIDELINESThis Clinical Practice Guideline is based upon the best information available at the time of publication. The recommendations are designed to provide information and assist decision-making. They are not intended to define a standard of care and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources and limitations unique to an institution or type of practice. Every healthcare professional making use of this Guideline is responsiblefor evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.